Unlock instant, AI-driven research and patent intelligence for your innovation.

Semi-solid and viscous liquid nasal formulations of cannabinoids

A cannabinoid, nasal technology, applied in non-active ingredients medical preparations, medical preparations containing active ingredients, liquid delivery, etc., can solve the problems of THC abuse, mucous membrane tissue dryness, mental illness recurrence, etc.

Pending Publication Date: 2019-05-21
ACERUS LABS INC
View PDF16 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oromucosal sprays may cause dryness and burning of the mucosal tissues, especially if any sores are present or during repeated chronic use
[0036] A transdermal delivery route for CBD was also investigated, but due to the highly lipophilic nature of CBD, a special ethosome delivery system was required to prevent the drug from accumulating in the skin, which was believed to be impractical and expensive at the time
[0037] CBD can also be obtained for therapeutic purposes by smoking CBD-rich cannabis, however, especially in the case of treating psychotic patients, this is the discouraged route of administration as this can lead to further THC abuse and further psychosis relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Semi-solid and viscous liquid nasal formulations of cannabinoids
  • Semi-solid and viscous liquid nasal formulations of cannabinoids
  • Semi-solid and viscous liquid nasal formulations of cannabinoids

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0208] Example 1: 15.5% Cannabinoids in a Castor Oil-Based Composition

[0209]Heat the castor oil to about 50°C. Dissolve THC and CBD in this heated castor oil under an inert atmosphere. Add colloidal silicon dioxide and homogenize to break up any lumps. Vacuum was applied with constant mixing to remove any entrapped air. Add oleoyl polyoxyethylene glyceride and continue mixing under vacuum. The vacuum was released with nitrogen and the product was cooled to below about 30°C with slow mixing. The ingredients were mixed in the proportions listed in Table 1 below.

[0210] Table 1

[0211]

example 2

[0212] Example 2: 15.5% Cannabinoids in a Castor Oil-Based Composition

[0213] Heat the castor oil to about 50°C. Dissolve THC and CBD in this heated castor oil under an inert atmosphere. Vacuum was applied with constant mixing to remove any entrapped air. Add oleoyl polyoxyethylene glyceride and continue mixing under vacuum. The vacuum was released with nitrogen and the product was cooled to below about 30°C with slow mixing. The ingredients were mixed in the proportions listed in Table 2 below.

[0214] Table 2

[0215]

example 3

[0216] Example 3: Sucrose Acetate Isobutyrate Based Composition with 15.5% Cannabinoids

[0217] The sucrose acetate isobutyrate was heated to about 50°C. Add and mix medium chain triglycerides, polyoxyethylene 35 hydrogenated castor oil and oleoyl polyoxyethylene glycerides under an inert atmosphere. Add and dissolve THC and CBD to create a clear solution. The ingredients were mixed in the proportions listed in Table 3 below.

[0218] table 3

[0219]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Cannabinoid containing pharmaceutical compositions suitable for nasal administration are disclosed. The compositions comprise the aforementioned cannabinoids and excipients selected such that the compositions are semi-solid or viscous liquids. In preferred embodiments, the cannabinoid is A9-tetrahydrocannabinol (THC) or cannabidiol (CBD). The excipients are preferably a mixture of an oily vehicle(such as castor oil or sucrose acetate isobutyrate) and a wetting agent / surfactant (such as oleoyl polyoxylglycerides). The compositions may further comprise thickeners (such as silicon dioxide) and other excipients. Methods for manufacturing and administering the compositions are disclosed, as well as methods for using the compositions in the treatment of disorders commonly known to be affected by cannabinoids.

Description

[0001] related application [0002] This U.S. patent application claims U.S. Provisional Application Serial No. 62 / 426,403 filed on November 25, 2016 and entitled "Cannabidiol Nasal Formulations" and filed on June 2, 2016 and entitled "Cannabidiol Nasal Formulations" Cannabidiol Nasal Formulations" U.S. Provisional Application Serial No. 62 / 344,486." Each of the aforementioned US Provisional Applications and the contents thereof are hereby incorporated by reference in their entirety. technical field [0003] The present invention relates to pharmaceutical cannabinoid compositions for topical application in the nasal cavity of a subject, methods of nasal use and methods of manufacture thereof. According to the present invention, the nasal cannabinoid composition of the present invention can be used as medical cannabis to treat or relieve or alleviate the symptoms of disorders or disease states, such as schizophrenia, epilepsy, pain, anxiety, cramping and migraine, wherein the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/05A61K47/44A61K9/00A61P25/00A61P29/00C07C39/23
CPCA61K9/0043A61K9/06A61K31/05A61K31/352A61K36/185A61K47/02A61K47/26A61K47/38A61K47/44A61P25/00A61P25/04A61P25/08A61P25/18A61P25/22A61P29/00A61K2300/00A61K47/14
Inventor N·布莱森A·C·莎玛
Owner ACERUS LABS INC